CA-SOUNDHOUND-INC.
SoundHound Inc. Ⓡ the leading innovator of voice-enabled AI and conversational intelligence technologies, today announced a milestone in its strategic partnership with Honda Motor Company with the integration of its Houndify voice AI platform into the new Honda e electric car and the top selling Honda Jazz in Europe. The Honda Personal Assistant—powered by Houndify—gives drivers an in-car conversational interface allowing them to control their environment, while accessing navigation, entertainment, and information hands-free. The personal assistant supports five major European languages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200827005197/en/
Houndify voice AI includes patented Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to deliver unprecedented speed and accuracy in voice recognition and responses. The platform’s ability to understand context, such as the user’s location or previous queries, eliminates the need to repeat information and allows more natural conversations.
Through the power of Houndify’s voice AI, drivers and passengers can ask Honda Personal Assistant even the most complex questions, such as: “OK Honda, show me restaurants within five kilometers, except French and Japanese ones, that have Wi-Fi, have at least three stars, and are open past 10 pm. ” Houndify’s ability to remember context allows for useful follow-up questions, such as “Does it have parking?” The natural language interface can proactively prompt for the next step, like directions to the destination. Deep navigation integration allows drivers to further the experience by asking questions such as, “Are there any convenience stores along the way?”
“Honda e is the first fully electric vehicle to feature Houndify’s voice AI platform, and Jazz is one of Honda’s most popular cars in Europe , ” said Keyvan Mohajer, CEO and co-founder of SoundHound Inc. “We are proud of our partnership with Honda Motor Company and look forward to the growing use of the Honda Personal Assistant in Europe.”
SoundHound Inc. and Honda Motor Company first announced their partnership in October 2018 and premiered their collaboration at the 2019 Tokyo Motor show, where they demonstrated the Honda Personal Assistant to positive reviews.
The voice-enabled Honda Personal Assistant is available on Honda e and select Honda Jazz models in French, German, Spanish, Italian, and English languages.
To learn more about Honda Personal Assistant, powered by Houndify, visit SoundHound Inc.’s Speech-to-Meaning blog .
Developers interested in exploring Houndify’s independent voice AI platform can visit Houndify.com to learn more and register for a free account.
About SoundHound Inc.:
SoundHound Inc. turns sound into understanding and actionable meaning. We believe in enabling humans to interact with the things around them in the same way we interact with each other: by speaking naturally to mobile phones, cars, apps, TVs, smart speakers, and every other part of the emerging ‘connected’ world. Our consumer app, Hound , leverages our Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to create a groundbreaking smartphone experience, and is the first product to build on the Houndify platform. Our SoundHound App applies our technology to music, enabling people to discover, explore, and share the music around them, and even find the name of that song stuck in their heads by singing or humming. Through the Houndify platform , we aim to bring voice-enabled AI to everyone and enable others to build on top of it. We call this Collective AI. Our Mission: Houndify everything.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom